HANNOVER, Germany, August 6 /PRNewswire/ -- BioVisioN AG, based in Hannover, Germany, has announced a change in its Supervisory Board. Effective July 1, 2004, Dr. Werner Schafer has joined the supervisory board of BioVisioN AG, replacing Erich Mayer. Dr. Schafer, Chairman of the BRAHMS AG, Berlin, has many years of experiences in the pharmaceutical and diagnostic industry. From 1995 to 2002 he was member of the executive committee of Roche Diagnostics GmbH. Before that he was Head of Area Operations and Scientific Development of ABBOTT Diagnostics GmbH.
"We are honoured and privileged to have Dr. Schafer join our Supervisory Board", said BioVisioN's CEO Dr Sven Rohmann. "It is great for our company that he will assist us with his profound knowledge of the pharmaceutical industry. Working with him we will gain important impulses for the further development of our company."
Supervisory Board and Management of BioVisioN AG thank Erich Mayer for the excellent and close collaboration in an important period of the company.
BioVisioN AG specialises in the identification of disease-relevant peptides and proteins, using its proprietary Peptidomics(R) technologies in order to discover new diagnostic markers, biomarkers and therapeutic leads in preclinical research and as Clinical Peptidomics in studies accompanying clinical trials. BioVisioN provides access to its technology in fee-for-service contracts as a Biological Research Organisation and also within larger scale research collaborations.
Contact: Dr. Rainer Voegeli, CBO
For further information please refer to http://www.biovision-discovery.de/
CONTACT: BioVisioN AG, Feodor-Lynen-Str. 5, 30625 Hannover, Tel:+49-511-538 896-0 Fax: +49-511-538 896-66 Contact: Dr. RainerVoegeli, CBO For further information please refer tohttp://www.biovision-discovery.de/